(Q33379343)

26 July 2017

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer (English)

1 reference

26 July 2017

phase II clinical trial

0 references

1 reference

2

Eric Van Cutsem

0 references

Patrick Schöffski

7

object named as

Patrick Schöffski

1 reference

26 July 2017

Johan Vansteenkiste

1

1 reference

26 July 2017

Herlinde Dumez

3

1 reference

26 July 2017

Cong Chen

4

1 reference

26 July 2017

Justin L Ricker

5

1 reference

26 July 2017

Sophia S Randolph

6

1 reference

26 July 2017

19 April 2008

1 reference

Investigational New Drugs

26 July 2017

1 reference

26 July 2017

26

1 reference

26 July 2017

483-488

1 reference

26 July 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-008-9131-6

26 July 2017

0 references

cites work

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

1 reference

12 December 2020

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells

1 reference

12 December 2020

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

12 December 2020

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo

1 reference

12 December 2020

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

1 reference

12 December 2020

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

1 reference

12 December 2020

Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

1 reference

12 December 2020

SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.

1 reference

12 December 2020

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies

1 reference

12 December 2020

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

12 December 2020

Histone deacetylase inhibitors: overview and perspectives

1 reference

12 December 2020

Histone deacetylase inhibitors in cancer therapy

1 reference

12 December 2020

Histone deacetylase inhibitors: molecular mechanisms of action

1 reference

12 December 2020

10.1007/S10637-008-9131-6

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kqnam7mjozgk3aujgd2wadayea

30 July 2022

mapped directly with Wikidata item

Dimensions Publication ID

1038891516

0 references

Fatcat ID

release_kqnam7mjozgk3aujgd2wadayea

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kqnam7mjozgk3aujgd2wadayea

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/kqnam7mjozgk3aujgd2wadayea

30 July 2022